Originally published In Press as doi:10.1074/jbc.M200015200 on March 13, 2002
J. Biol. Chem., Vol. 277, Issue 22, 19639-19648, May 31, 2002
Interactions between Fission Yeast mRNA Capping
Enzymes and Elongation Factor Spt5*
Yi
Pei and
Stewart
Shuman
From the Molecular Biology Program, Sloan-Kettering Institute,
New York, New York 10021
Received for publication, January 2, 2002, and in revised form, March 5, 2002
 |
ABSTRACT |
Elongating RNA polymerase II is targeted by
macromolecular assemblies that regulate mRNA synthesis and
processing. The capping apparatus is the first of the assemblies to act
on the nascent pre-mRNA. Although recruitment of the capping
enzymes to the transcription complex is dependent on phosphorylation of
the C-terminal domain of the Rpb1 subunit of polymerase II
(Pol-II), there may be additional levels of control that coordinate
capping with elongation. Here we show that the triphosphatase (Pct1)
and guanylyltransferase (Pce1) enzymes of the fission yeast capping
apparatus bind independently to the elongation factor Spt5. The
C-terminal domain of the 990-amino acid Schizosaccharomyces
pombe Spt5 protein, composed of repeats of a nonapeptide
motif (consensus sequence TPAWNSGSK), is necessary and sufficient for
binding to the capping enzymes in vivo (in a two-hybrid
assay) and in vitro. As few as four nonamer repeats suffice
for Spt5 binding to Pct1 in vitro, whereas six repeats are
required for Spt5 binding to Pce1. A 116-amino acid fragment of the
guanylyltransferase Pce1 suffices for binding to the Spt5 C-terminal
domain (CTD) but not for binding to the Pol-II CTD. Pct1 and Pce1 can
bind simultaneously to the Spt5 CTD in vitro. We find that
Spt5 is essential for viability of S. pombe and that it
interacts in vivo with S. pombe Spt4 via a
central domain distinct from the Spt5 CTD. We suggest that Spt5-induced
arrest of elongation at promoter proximal positions ensures a temporal
window for recruitment of the capping enzymes.
 |
INTRODUCTION |
mRNA capping occurs cotranscriptionally by a series of three
enzymatic reactions in which the 5' triphosphate terminus of the
pre-mRNA is cleaved to a diphosphate by RNA triphosphatase, then
capped with GMP by RNA guanylyltransferase, and methylated at the N7
position of guanine by RNA (guanine-7) methyltransferase (1). Targeting
of cap formation to transcripts made by RNA polymerase II
(Pol-II)1 is achieved, at
least in part, through physical interactions of one or more components
of the capping apparatus with the phosphorylated C-terminal domain
(CTD) of the largest subunit of Pol-II (2-5). The Pol-II CTD is
composed of a tandemly repeated heptad motif (consensus sequence
YSPTSPS), which undergoes a cycle of extensive serine phosphorylation
and dephosphorylation during the transcription cycle.
In the budding yeast Saccharomyces cerevisiae, the
guanylyltransferase and methyltransferase components of the capping
apparatus bind independently in vitro and in vivo
to the phosphorylated Pol-II CTD (2, 6). The S. cerevisiae
RNA triphosphatase does not bind to the Pol-II CTD by itself (7), but
it does bind to the guanylyltransferase (8-10). The mammalian capping enzyme (Mce1) is a bifunctional polypeptide composed of an N-terminal RNA triphosphatase domain linked to a C-terminal guanylyltransferase domain. The guanylyltransferase domain per se binds to
Pol-II CTD-PO4, but the triphosphatase domain does not (5,
11). The fission yeast Schizosaccharomyces pombe employs a
unique strategy of cap targeting whereby the triphosphatase (Pct1) and
guanylyltransferase (Pce1) enzymes of the capping apparatus are not
associated physically with each other (as they are in budding yeast and
metazoans) but instead bind independently to the phosphorylated Pol-II
CTD (12).
Although interactions between Pol-II and capping enzymes offer a
satisfying explanation for the specific capping of nascent pre-mRNAs, it is conceivable that other factors are also involved in linking capping to transcription. For example, Wen and Shatkin reported that hSpt5, the human homolog of yeast transcription elongation factor Spt5, interacts directly with the mammalian capping
enzyme (13). hSpt5 translated in vitro binds independently to the N-terminal triphosphatase and C-terminal guanylyltransferase domains of Mce1. Human immunodeficiency virus (HIV) employs yet another
mechanism to recruit the capping enzyme to the HIV transcription unit,
whereby the viral Tat protein binds directly and independently to the
triphosphatase and guanylyltransferase domains of Mce1 and up-regulates
both catalytic activities (14).
Spt5 and Tat are intimately connected to the regulation of HIV gene
expression. hSpt5 (a 1087-amino acid polypeptide) and its binding
partner hSpt4 (a 117-amino acid polypeptide) comprise the transcription
elongation regulatory factor DSIF (DRB sensitivity inducing factor)
(15, 16). DSIF binds to Pol-II and, in concert with the negative
elongation factor (NELF), represses elongation at
promoter-proximal positions in the transcription unit (17, 18). Escape
from the repressive effect of DSIF/NELF requires the action of P-TEFb
(Positive Transcription Elongation Factor b), a DRB-sensitive protein
kinase that phosphorylates both the CTD of the largest subunit of RNA
polymerase II and the Spt5 subunit of DSIF (19-23). P-TEFb is composed
of two subunits, Cdk9 and cyclin T, and it binds to the HIV Tat protein
via the cyclin T subunit (20). In the case of HIV, it has been
suggested that: (i) Spt5-induced arrest at promoter-proximal sites
prolongs the opportunity for recruitment of the mammalian capping
enzyme to the elongation complex through a multiplicity of Mce1
interactions with Tat, Spt5, and the Pol-II CTD and (ii) Tat directly
enhances the efficiency of capping of the HIV pre-mRNA (14).
It is not yet clear whether and how the capping apparatus fits into the
Spt5 regulatory axis during gene expression in yeast. By studying the
macromolecular interactions of the S. pombe capping apparatus in vivo using a two-hybrid approach, we have
identified the essential S. pombe Spt5 protein as a binding
partner of the triphosphatase (Pct1) and guanylyltransferase (Pce1)
components of the fission yeast capping machinery. We show that the
C-terminal nonapeptide repeat domain of S. pombe Spt5 binds
avidly and independently to Pct1 and Pce1 in vitro. A
discrete domain of Pce1 suffices for binding to Spt5. We hypothesize
that the purpose of the Spt5/capping enzyme interaction is to ensure
timely capping of the nascent pre-mRNA before committing Pol-II to
processive elongation.
 |
EXPERIMENTAL PROCEDURES |
Yeast Two-hybrid Screen--
The screen was performed as
described previously using binding domain (BD)-Pce1 and BD-Pct1 as the
bait (12). Plasmid DNA recovered from the strains that tested positive
for both HIS3 and lacZ expression was used as the
template for PCR amplification of the S. pombe DNA insert
with flanking primers specific for the activation domain (AD) fusion
plasmid. The PCR products were gel-purified and then sequenced. The AD
plasmid clones were recovered after transformation into E. coli DH5
.
Spt5, Pct1, and Pce1 Truncation Mutants--
Gene fragments
encoding N-terminal-truncated versions of S. pombe Spt5 were
generated by PCR amplification using sense primers that introduced a
BamHI site at the 5' end of the truncated Spt5 coding region
and an antisense primer that introduced an XhoI site
immediately downstream of the stop codon. Gene fragments encoding
C-terminal-truncated versions of Spt5 were generated by PCR
amplification using antisense primers that introduced stop codons in
lieu of the codons for amino acids 961, 925, 899, or 801, and a
XhoI site immediately 3' of the stop codon. The PCR products
were digested with BamHI and XhoI and then
inserted into the two-hybrid AD fusion vector pGAD-GH.
Gene fragments encoding N-terminal truncated versions of Pce1 were
generated by PCR amplification using sense primers that introduced an
NcoI site at the 5' end of the truncated coding region and
an antisense primer that introduced a BamHI site immediately downstream of the stop codon. Gene fragments encoding C-terminal truncated versions of Pce1 were generated by PCR amplification using
antisense primers that introduced stop codons in lieu of the codons for
amino acids 351, 301, or 251 and a BamHI site immediately 3'
of the stop codon. The PCR products were digested with NcoI and BamHI and then inserted into the two-hybrid BD fusion
vector pAS2-1.
Gene fragments encoding N-terminal-truncated versions of Pct1 were
generated by PCR amplification using sense primers that introduced an
NdeI site at the codons for amino acids 21, 41, 51, 61, or
77. The antisense primers introduced a BamHI site
immediately downstream of the stop codon. The PCR products were
digested with NdeI and BamHI and then inserted
into pAS2-1.
The full-length S. pombe SPT4 gene was PCR-amplified from
genomic DNA using primers that introduced an NdeI site at
the start codon and a BamHI site immediately 3' of the stop
codon. The PCR product was digested with NdeI and
BamHI and then inserted into pAS2-1. All of the
inserts were sequenced to ensure that the truncated SPT5,
PCT1, or PCE1 genes were fused in-frame to BD or
AD and that no unwanted coding changes had been introduced during
amplification and cloning.
Recombinant Capping Enzymes--
S. pombe
guanylyltransferase Pce1 and RNA triphosphatase Pct1 were produced in
E. coli as N-terminal His10-tagged fusions and
purified from soluble bacterial lysates by nickel-agarose chromatography as described previously (12, 24). Recombinant Pce1
without an affinity tag was produced as follows. A DNA fragment containing the complete PCE1 cDNA with a
BamHI restriction site at each end was inserted into the
bacterial expression vector pET28-His6-Smt3 so as to fuse
the PCE1 cDNA in-frame to His6-Smt3. The resulting plasmid pET28-Smt3-PCE1 was introduced into E. coli BL21(DE3). A 200-ml culture was grown from a single
kanamycin-resistant transformant at 37 °C in Luria-Bertani medium
containing 60 µg/ml kanamycin until the A600
reached 0.5. The culture was placed on ice for 30 min and then adjusted
to 0.5 mM
isopropyl-1-thio-
-D-galactopyranoside and 2% (v/v)
ethanol. Incubation was continued for 20 h at 18 °C with
constant shaking. Cells were harvested by centrifugation, and the
pellets were stored at
80 °C. All subsequent procedures were
performed at 4 °C. Thawed bacteria were resuspended in 10 ml of
lysis buffer (50 mM Tris-HCl, pH 7.5, 200 mM
NaCl, 10% sucrose). Lysozyme was added to a final concentration of 100 µg/ml; the suspension was incubated on ice for 10 min and then
sonicated for 30 s. Triton X-100 was added to a final
concentration of 0.1%, and sonication was repeated to reduce the
viscosity of the lysate. Insoluble material was removed by
centrifugation for 45 min at 17,000 rpm in a Sorvall SS34 rotor. The
soluble extract was applied to a 1-ml column of Ni-NTA-agarose that had
been equilibrated with lysis buffer containing 0.1% Triton X-100. The
column was washed with the same buffer and then eluted stepwise with
buffer B (50 mM Tris-HCl, pH 8.0, 200 mM NaCl,
10% glycerol, 0.05% Triton X-100) containing 50, 100, 200, and 500 mM imidazole. The polypeptide compositions of the column
fractions were monitored by SDS-PAGE. The His6-Smt3-Pce1
fusion protein was retained on the column and recovered predominantly
in the 100 mM imidazole fraction. The eluate was dialyzed
overnight against buffer B to remove imidazole. The fusion protein was
then digested with purified recombinant Ulp1 (25) at a
Ulp1/His6-Smt3-Pce1 ratio of 1:200 (w/w) for 2 h on
ice. The digested material was applied to a 1-ml column of
Ni-NTA-agarose that had been equilibrated with buffer B. Native Pce1 (1 mg) was recovered in the flow-through fraction. Protein concentrations
were determined by using the BioRad dye reagent with bovine serum
albumin as the standard.
Recombinant GST-Spt5 Fusion Proteins and Native Spt5
CTD--
The open reading frames encoding Spt5(801-990),
Spt5(801-898), Spt5(845-898), and Spt5(845-880) were PCR-amplified
using primers that introduced an NcoI site at the 5' end and
an XhoI site immediately 3' of the stop codon. The PCR
products were digested with NcoI and XhoI and
inserted into the pGEX-KG vector. The resulting plasmids encode
glutathione-S-transferase (GST)-Spt5 fusion proteins. The inserts were sequenced to verify that no unwanted coding changes had
been introduced during amplification and cloning. Plasmids encoding GST
and the GST-Spt5 fusion proteins were transformed into E. coli BL21(DE3). Single transformants were grown at 37 °C in 100 ml of Luria-Bertani medium containing 100 µg/ml ampicillin until the
A600 reached 0.5. The cultures were placed on
ice for 30 min and then adjusted to 0.5 mM
isoprooyl-1-thio-
-D-galactopyranoside and 2% (v/v)
ethanol. Incubation was continued for 20 h at 18 °C with
constant shaking. Cells were harvested by centrifugation. GST and the
GST-Spt5 fusion proteins were purified from soluble lysates by
affinity chromatography on a glutathione-Sepharose 4B resin according
to the instructions of the vendor (Pharmacia). GST and the GST-Spt5
fusion proteins were eluted from the resin with buffer containing 10 mM glutathione, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10% glycerol, and 0.05% Triton X-100. The elutes were dialyzed against buffer containing 50 mM Tris HCl, pH
8.0, 100 mM NaCl, 1 mM DTT, 10% glycerol, and
0.05% Triton X-100 and stored at
80 °C.
Recombinant Spt5(801-990) without an affinity tag was produced by
cloning the open reading frame into the bacterial expression vector
pET28-His6-Smt3 so as to fuse Spt5(801-990) in-frame to His6-Smt3. The His6-Smt3-Spt5(801-990) protein
was produced in bacteria, purified by nickel-agarose chromatography,
and digested with Ulp1 to remove the tag. The Spt5(801-990) protein
was then purified free of the tag using methods described above for
His6-Smt3-Pce1.
Protein Affinity Chromatography--
20 µg of purified
His-Pct1 or His-Pce1 was adsorbed to 50 µl of Ni-NTA-agarose beads
(Qiagen) during a 1-h incubation at 4 °C in 500 µl of binding
buffer 1 (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 20 mM imidazole, and 0.005% Tween
20). The beads were washed once with 0.5 ml of binding buffer 1 to
remove any unbound protein. The beads were then mixed for 1 h at
4 °C with 5 µg of purified GST or GST-Spt5 in 300 µl of binding
buffer 1. The beads were then concentrated by microcentrifugation, and
the supernatant was withdrawn. The beads were resuspended in 0.5 ml of
binding buffer 1 and subjected to two rounds of concentration and
washing. After the second wash, the bound proteins were eluted with 50 µl of binding buffer 1 containing 250 mM imidazole.
Aliquots (25 µl) of the input and the bead-bound fractions were
analyzed by SDS-PAGE.
20 µg of purified GST or GST-Spt5 fusion protein was adsorbed to 50 µl of GSH-Sepharose beads during a 1-h incubation at 4 °C in 300 µl of binding buffer 2 (50 mM Tris HCl, pH 8.0, 50 mM NaCl, 5% glycerol, 1 mM DTT, 0.03% Triton
X-100). The beads were then washed twice with 1 ml of binding buffer 2 to remove unbound protein. Then the beads were mixed with 5 µg of
purified His-Pct1 or His-Pce1 for 1 h at 4 °C in 50 µl of
binding buffer 2. The beads were then concentrated by
microcentrifugation, and the supernatant was withdrawn. The beads were
resuspended in 1 ml of binding buffer 2 and subjected to two rounds of
concentration and washing. After the second wash, the bound proteins
were eluted with 50 µl of binding buffer 2 containing 10 mM glutathione. Aliquots (25 µl) of the input and the
bead-bound fractions were analyzed by SDS-PAGE.
For detection of ternary complex formation, a mixture containing
either: (i) 20 µg of His-Pct1 and 40 µg of Spt5(801-990), (ii) 20 µg of His-Pct1 alone, or (iii) 40 µg of Spt5(801-990) alone was
incubated for 1 h at 4 °C with 50 µl of Ni-NTA-agarose beads
in 300 µl of binding buffer 3 (50 mM
NaH2PO4, pH 8.0, 50 mM NaCl, 20 mM imidazole, 0.005% Tween 20). The beads were then washed
once with 0.5 ml of binding buffer 3 to remove any unbound protein.
Then the beads were incubated with 10 µg of purified Pce1 in 100 µl
of binding buffer 3. After incubation for 2 h at 4 °C, the
beads were concentrated by microcentrifugation, and the supernatant was
withdrawn. The beads were resuspended in 0.5 ml of binding buffer 3 and
subjected to two rounds of concentration and washing. After the second
wash, the bound proteins were eluted with 50 µl of binding buffer 3 containing 250 mM imidazole. Aliquots (25 µl) of the
input and the bead-bound fractions were analyzed by SDS-PAGE.
 |
RESULTS |
S. pombe Triphosphatase and Guanylyltransferase Interact with S. pombe Spt5 in Vivo--
A two-hybrid screen of ~200,000
transformants for guanylyltransferase-interacting proteins using a Gal4
DNA-BD-Pce1 fusion as bait yielded 11 His+ isolates, two of
which contained plasmids encoding the Gal AD fused in-frame to
C-terminal fragments of a predicted 990-amino acid S. pombe
polypeptide with extensive similarity to human Spt5. Two different
AD-Spt5 fusion clones were isolated: AD-Spt5(165-990) and
AD-Spt5(556-990) (Fig. 1). Control
experiments showed that the His+ and
lacZ+ phenotypes required cotransformation with
BD-Pce1 and AD-Spt5(165-990) plasmids and that neither fusion plasmid
was able to drive expression of the HIS3 or lacZ
reporter genes when cotransformed with the BD or AD vectors (Fig.
2A).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
S. pombe capping enzymes interact
with S. pombe Spt5 in
vivo. Plasmids encoding the indicated AD-Spt5 fusions
were transformed into S. cerevisiae Y190 cells bearing the
BD-Pce1 or BD-Pct1 plasmids. The limits of the Spt5 polypeptide segment
of the fusion protein are indicated and drawn to scale as horizontal
lines. The nonamer repeats are depicted as vertical bars.
The AD-Spt5 fusions that were recovered in the two-hybrid screen of the
S. pombe cDNA library are indicated by check
marks. Other derivatives were engineered by PCR-based
site-directed mutagenesis. Single Trp+ Leu+
isolates were selected and streaked on SD( Trp, Leu, His, 3-AT)
agar medium to test for HIS3 expression. Robust growth on
selective medium was scored as ++ (see Fig. 2A). Strains
that grew no better than the BD-Pce1 plus AD controls (see Fig.
2A) were scored as . Intermediate levels of growth were
scored as + on the basis of His+ colony size.
|
|

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 2.
Specificity of the Pce1-Spt5 and Spt4-Spt5
two-hybrid interactions. The BD-Pce1, BD-Spt4, and
AD-Spt5(165-990) fusion plasmids and the BD and AD vectors without
inserts were transformed pairwise into S. cerevisiae Y190.
Single Trp+ Leu+ isolates containing the
indicated plasmid pairs were selected and streaked on SD( Trp, Leu,
His, 3-AT) agar medium. The plates were photographed after incubation
for 5 days at 30 °C. Trp+ Leu+ isolates
containing the indicated plasmid pairs were patched on SD( Trp, Leu)
agar medium. The cell patches were photographed after incubation for 1 day at 30 °C (Growth). The cell patches were then tested for
-galactosidase activity using the colony-lift filter assay.
Photographs of the filters are shown (lacZ). A shows the
interactions of Pce1 and Spt5. B shows the interaction of
Spt4 and Spt5.
|
|
A two-hybrid screen of ~100,000 transformants for
triphosphatase-interacting proteins using a BD-Pct1 fusion as bait
yielded 16 His+ isolates, of which four contained plasmids
encoding the AD fused in-frame to C-terminal fragments of S. pombe Spt5. Two different AD-Spt5 fusion clones were isolated:
AD-Spt5(628-990) was recovered three times and AD-Spt5(772-990) was
isolated once (Fig. 1). Control experiments confirmed that
HIS3 and lacZ expression required
cotransformation with the BD-Pct1 and AD-Spt5(628-990) plasmids (not shown).
A C-terminal Spt5 Domain Suffices for Interaction with S. pombe
Capping Enzymes in Vivo--
The AD-Spt5 fusions that interacted
in vivo with Pce1 or Pct1 contained at their C termini 18 tandem copies of a nonapeptide repeat (consensus sequence TPAWNSGSK),
plus a variable segment of the Spt5 protein upstream of the start of
the repeats (Figs. 1 and 4A). To gauge the role of the
non-reiterative protein segment, we engineered a series of AD-Spt5
clones in which the fusion junction was moved incrementally toward the
start of the repeat region. These clones were tested in a directed
two-hybrid assay paired with BD-Pce1 and BD-Pct1. We found that the
Spt5 interaction with both capping enzymes persisted when the AD fusion
started from position 801 and contained little more than the C-terminal
repeats per se (Fig. 1). Thus, the entire N-terminal
800-amino acid segment was dispensable for interaction with the capping
enzymes. On the other hand, deletion of the C-terminal 190-amino acid
segment containing all of the nonamer repeats, i.e. in the
fusion clone AD-Spt5(165-800), completely abolished the
two-hybrid interaction with Pce1 and Pct1 (Fig. 1).
Interaction of Proximal and Distal Nonamer Repeats with Pce1 and
Pct1 in Vivo: Redundant and Unique Features--
To define the minimal
segment of the Spt5 C-terminal domain (Spt5 CTD) capable of interacting
with the capping enzymes, we tested a finer series of deletion variants
in the two-hybrid assay (Fig. 1). We found that the Spt5 interaction
with the RNA triphosphatase Pct1 persisted with undiminished strength
(as gauged by colony size during selection for His+) after
elimination of the proximal six nonamer repeats, i.e. in
Spt5(863-990), but was abolished after deletion of the next eight and
six nonamer repeats in Spt5(899-990) and Spt5(917-990), respectively
(Fig. 1). Apparently, the C-terminal twelve repeats sufficed for Spt5
binding to Pct1 in vivo, but the C-terminal eight and six
repeats did not. From the opposite direction, we found that elimination
of three, five, or eight nonamers from the C terminus of Spt5 had no
effect on its interaction with Pct1 (Fig. 1). Thus, the first ten
repeats (upstream of amino acid 898) were sufficient for Pct1 binding
in vivo. This analysis indicates that the proximal
(801-898) and distal (863-990) nonamer arrays of the Spt5 CTD are
functionally redundant with respect to Pct1 binding.
The two-hybrid interaction of Spt5 with the guanylyltransferase Pce1
displayed a more stringent requirement for Spt5 CTD length. Binding of
Pce1 was abolished by deletion of as few as three upstream nonamers (in
Spt5(836-990)) indicating that the remaining 15 C-terminal nonamers
were insufficient. Pce1 binding persisted, albeit with diminished
strength, upon elimination of three, five, or eight nonamers from the C
terminus of Spt5 (Fig. 1). Thus, with respect to Pce1 binding the
proximal and distal repeats are functionally distinct. Note that the
proximal nonamers adhere more closely to the consensus sequence than do
the distal repeats (Fig. 4A).
S. pombe Spt5 Is Essential for Cell Viability and Interacts with S. pombe Spt4--
There have been no antecedent studies of Spt5 from
fission yeast. Thus, we asked two questions. (i) Is Spt5 essential in
S. pombe? (ii) Does S. pombe Spt5 interact with a
homolog of Spt4? To address the first issue, we constructed a deletion
allele of S. pombe spt5+ in which the coding
sequences for amino acids 1-990 was removed and replaced by the
bacterial kanamycin resistance gene. The
spt5::kanMX construct was transformed
into a diploid strain of S. pombe and chromosomal
integrants containing one copy of wild-type
spt5+ and one of
spt5::kanMX were selected on medium
containing G418. Correct integration was confirmed by diagnostic PCR
amplification of genomic DNA from the heterozygote. We then sporulated
the heterozygote, dissected tetrads, and scored for spore viability and
the presence of the kanMX marker. We found that 10 of the 10 tetrads yielded only two viable spores, and all of the viable haploids
were G418-sensitive, i.e. none contained the
spt5::kanMX allele. We conclude that
the spt5+ gene, which we isolated in the
two-hybrid screen against the capping enzymes, is essential for cell
growth in S. pombe.
The fission yeast gene encoding a 104-amino acid homologue of human
Spt4 (GenBankTM accession no. AL157918) was fused to
the Gal4 DNA binding domain, and the resulting BD-Spt4 construct was
tested in a directed two-hybrid assay for interaction with S. pombe Spt5. Their interaction in vivo was evinced by
histidine prototrophy and lacZ expression in yeast cells
cotransformed with the BD-Spt4 and AD-Spt5(165-990) plasmids (Fig.
2B). Neither plasmid alone was able to activate HIS3 or lacZ. An additional experiment showed
that the C-terminal deletion variant Spt5(165-800), which lacks the
entire nonamer repeat array, retains its interaction with Spt4 in the
two-hybrid assay as does the even shorter fragment Spt5(165-400) (not
shown). Thus, there are distinct and non-overlapping binding sites for Spt4 and the mRNA capping enzymes on the S. pombe Spt5 protein.
Capping Enzymes Have Distinct Structural Requirements for Binding
to Spt5 and the Pol-II CTD--
The S. pombe
guanylyltransferase Pce1 is a 402-amino acid monomeric protein (26).
The active site of nucleotidyl transfer is composed of six motifs (I,
III, IIIa, IV, V, and VI) that are conserved in order and spacing in
the guanylyltransferases of all eukaryotes and several families of
eukaryotic DNA viruses (1). RNA guanylyltransferase consists of two
structural domains (27). The larger N-terminal domain (domain 1)
includes motifs I, III, IIIa, and IV. The smaller C-terminal domain 2 includes motif VI. Motif V comprises the linker segment connecting
domains 1 and 2. To gauge whether Pce1 contains a discrete functional domain for binding to Spt5, we engineered a series of Pce1 deletion variants as BD fusions and tested them for two-hybrid interaction with
AD-Spt5(165-990) (Fig. 3A).
Pce1(235-402), consisting of motif V plus domain 2, retained full
activity in the two-hybrid binding assay with Spt5; thus, domain 1 is
not required for guanylyltransferase binding to Spt5. Further deletion
of the segment from amino acids 235-260, which eliminates motif V,
results in the loss of in vivo binding to Spt5, suggesting
that motif V may comprise part of the Spt5 binding site. Spt5 binding
was retained upon deletion of the C-terminal segment of Pce1 from
residues 351-402 but was abolished by a more extensive deletion
embracing residues 301-402 (Fig. 3A). A 116-amino acid
fragment of the guanylyltransferase extending from residues 235-350
sufficed for the interaction with Spt5 (Fig. 3A). In stark
contrast, the two-hybrid interaction of Pce1 with the C-terminal domain
of Rbp1, the largest subunit of S. pombe Pol-II, was
abrogated by every one of the Pce1 deletions tested (Fig.
3A). We surmise that the structural requirements for Pce1
binding to Pol-II CTD are more complex than those for its binding to
Spt5.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of Pce1 and Pct1 deletion mutations
on their binding interactions in vivo. A, the
402-amino acid Pce1 polypeptide is depicted as a horizontal line
with the six nucleotidyl transferase motifs (I,
III, IIIa, IV, V,
and VI) shown as boxes. B,
the 301-amino acid Pct1 polypeptide is depicted as a horizontal line
with the metal-binding motifs A and C
shown as boxes. The limits of the truncated derivatives of
Pce1 and Pct1 are indicated and drawn to scale as horizontal lines.
Plasmids encoding the BD fusions were introduced into yeast cells
containing plasmids encoding AD fusions to S. pombe
Spt5(165-990) or the Pol-II CTD, Rpb1(1324-1752). The strengths of
the pairwise two-hybrid interactions were scored as described in Fig.
1.
|
|
The S. pombe RNA triphosphatase Pct1 is a 303-amino acid
polypeptide with a homodimeric quaternary structure (24). The
phosphohydrolase active site includes two glutamate-containing motifs
(A and C) that comprise the binding site for the essential divalent
cation cofactor. Motifs A and C are widely separated in the primary
structure (Fig. 3B) but are closely positioned in the
enzyme's tertiary structure (28). Fungal RNA triphosphatases display
considerable variability in the length and amino acid sequence of the
segments upstream of motif A. To assess the role of this region in the binding of Pct1 to Spt5, we constructed a series of N-terminal Pct1
deletions and tested them in the two-hybrid assay (Fig. 3B). Removal of 20, 40, or 50 amino acids from the N terminus of Pct1 did
not affect its in vivo binding to Spt5, but a further
deletion of residues 51-60 abolished Spt5 binding. The in
vivo interaction of Pct1 with the Pol-II CTD was unaffected by
deletion of 20 or 40 amino acids but was abolished by removal of amino
acids 41-50 (Fig. 3B).
Binding of S. pombe Capping Enzymes to Spt5 in Vitro--
We used
affinity chromatography to analyze the interaction of capping enzymes
with Spt5 in vitro. Fusion proteins containing GST linked to
the complete CTD Spt5(801-990), to the first ten nonamer repeats
Spt5(801-898), and to an internal segment Spt5(845-898) containing
six consensus repeats were produced in bacteria and purified. The GST
fusions were mixed with purified recombinant His10-Pct1
protein that had been immobilized on nickel-agarose beads (Fig.
4B). The material that
adsorbed to the resin, remained bound after extensive washing, and was
subsequently eluted with 250 mM imidazole (bound fraction
B) was analyzed by SDS-PAGE in parallel with the input GST fusion
protein (load fraction L). Virtually all of the input
GST-Spt5(801-990) was adsorbed to the nickel-agarose/His-Pct1 beads
and recovered in the imidazole eluate along with the His-Pct1 protein
(Fig. 4B). In contrast, purified GST failed to bind to the
nickel-agarose/His-Pct1 beads. Thus, we attribute the binding to the
Spt5(801-990) component of the fusion protein. Additional control
experiments verified that none of the input GST-Spt5(801-990) protein
was retained on nickel-agarose beads alone (not shown). The
GST-Spt5(801-898) and GST-Spt5(845-898) proteins also bound nearly
quantitatively to the nickel beads containing His-Pct1 (Figs.
4B and 5B) but not
at all to nickel-agarose beads alone (not shown). An even shorter
fusion protein, GST-Spt5(845-880), composed of just four nonamers also
bound to the beads containing His-Pct1; however, the extent of binding
was diminished by about half compared with the fusion protein with six
nonamers. We conclude that: (i) four consensus nonamer repeats are
sufficient for direct binding of Pct1 to Spt5 and (ii) phosphorylation
of the Spt5 CTD is not required for Pct1 binding.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 4.
The C-terminal nonamer repeat domain of Spt5
binds to S. pombe capping enzymes in
vitro. A, the Spt5 CTD from amino
acids 801 to 990 is displayed with the nonamer repeats aligned
vertically. The consensus sequence TPAWNSGSK is
shown below the alignment. Only modules containing a proline at
position 2 are counted as CTD repeats. B and C,
aliquots (5 µg) of GST, GST-Spt5(801-990), GST-Spt5(801-898) or
GST-Spt5(845-898) were subjected to affinity chromatography using
nickel-agarose beads containing either His-Pct1 (B) or
His-Pce1 (C). Aliquots comprising 50% of the input GST or
GST-Spt5 fusion (lanes L) and 50% of the
bead-bound material (lanes B) were analyzed by SDS-PAGE. The
polypeptides were visualized by staining with Coomassie Blue dye.
His-Pct1 (B) and His-Pce1 (C) are denoted by
arrows on the right. The positions of various
GST-Spt5 fusion proteins are denoted by dots ( ) next to the stained
polypeptides in lanes B. The positions and sizes (in kDa) of
marker proteins are indicated on the left.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Four nonamer repeats suffice for Spt5 binding
to Pct1 but not Pce1. A, the Spt5 CTD from amino acids
845 to 898 is displayed with the nonamer repeats aligned vertically.
Aliquots (5 µg) of GST-Spt5(845-898) or GST-Spt5(845-880) were
subjected to affinity chromatography using nickel-agarose beads
containing either His-Pct1 (B) or His-Pce1 (C).
Aliquots comprising 50% of the input GST-Spt5 fusion (lanes
L) and 50% of the bead-bound material (lanes B) were
analyzed by SDS-PAGE. The polypeptides were visualized by staining with
Coomassie Blue dye.
|
|
Similar nickel-agarose chromatography experiments were performed using
recombinant His10-Pce1 (Fig. 4C). Although the
GST-Spt5(801-990) fusion protein is not well separated from the 47-kDa
His-Pce1 polypeptide during SDS-PAGE, it was still apparent that nearly all of the input GST-Spt5(801-990) adsorbed to the
nickel-agarose/His-Pce1 beads, whereas purified GST did not bind to the
beads (Fig. 4C). The GST-Spt5(801-898) protein also bound
nearly quantitatively to the nickel beads containing His-Pce1 (Fig.
4C), but there was an obvious decrease in the extent of
binding by the GST-Spt5(845-898) fusion protein, which contains only
six consensus nonamers (Figs. 4C and 5C). We
observed no binding of Pce1 to the GST-Spt5(845-880) fusion protein
containing four nonamer repeats (Fig. 5C). These data show
that binding of Spt5 to Pce1 is direct and confirm the inference from
the two-hybrid analysis (Fig. 1) that the Spt5 CTD length requirements
are more stringent for Spt5 binding to Pce1 than for its binding to Pct1.
The direct nature of the Spt5 interaction with the capping enzymes
in vitro was confirmed by reciprocal affinity chromatography experiments that exploited the GST domain as the affinity tag. GST and
the GST-Spt5 fusions were immobilized on glutathione-Sepharose beads,
which were then mixed with purified His-Pct1. The input His-Pct1 (Fig.
6A, lane 1) was
analyzed by SDS-PAGE along with the material that bound to the GSH
resin and was subsequently stripped off with glutathione (bead-bound
fractions, lanes 2-4). We found that His-Pct1 bound avidly
to the GSH beads containing the GST-Spt5(801-990) fusion, but did not
bind at all to GSH beads alone or to GSH beads containing just GST
(Fig. 6A). Fig. 6B shows that the
guanylyltransferase His-Pce1 bound to beads containing the
GST-Spt5(801-898) fusion but did not bind at all to the beads alone or
to beads containing GST.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 6.
Binding of S. pombe capping
enzymes to GST-Spt5. Aliquots (5 µg) of His-Pct1
(A) or His-Pce1 (B) were
subjected to affinity chromatography using glutathione (GSH)
beads containing GST, GST-Spt5(801-990), or GSH beads alone. Aliquots
comprising 50% of the input capping enzymes and 50% of the bead-bound
fractions were analyzed by SDS-PAGE. The polypeptides were visualized
by staining with Coomassie Blue dye. The identities of the polypeptides
are denoted by arrows on the right. The positions
and sizes (in kDa) of marker proteins are indicated on the
left.
|
|
The binding of GST-Spt5(801-990) to Pce1 had no effect on its
guanylyltransferase activity in vitro; GST-Spt5(801-990)
binding also had no effect on the triphosphatase activity of Pct1 (data not shown).
Simultaneous Binding of Pct1 and Pce1 to the Spt5 CTD--
An
important mechanistic question is whether the two cap-forming enzymes
bind in a mutually exclusive fashion to the CTD of Spt5 or whether they
can bind simultaneously to a single molecule of Spt5 CTD. To test these
scenarios, we established an indirect affinity chromatography assay in
which the binding of the guanylyltransferase to an affinity resin
containing the triphosphatase would be strictly contingent on the
action of Spt5 CTD as a molecular bridge (Fig. 7). The success of this assay requires
that: (i) Pct1 be the only macromolecule that contains an affinity tag
for linkage to the beads (in this case, a His tag) and (ii) the
bridging component Spt5 cannot be fused to GST because GST will
inherently homodimerize and thereby confound the issue of whether the
assay readout reflects the binding of Pct1 and Pce1 to the same
molecule of Spt5 (the model being tested) or to two different molecules
of Spt5 connected via the GST domain.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 7.
Pct1 and Pce1 bind simultaneously to
Spt5(801-990). A, schematic illustration of the
strategy for detection by affinity chromatography of a ternary complex
of His-Pct1 and Pce1 bound to the Spt5 CTD. See "Results"
for details. B, glycerol gradient sedimentation. Aliquots
(50 µg) of the "non-tagged" recombinant Spt5(801-990) and Pce1
proteins were mixed with marker proteins catalase, bovine serum
albumin, and cytochrome c (50 µg each) in 0.2 ml of buffer
containing 50 mM Tris-HCl, pH 8.0, 200 mM NaCl,
and 10% glycerol. The mixtures were layered onto 4.8 ml 15-30%
glycerol gradients containing 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM DTT, and 0.1% Triton X-100. The
gradients were centrifuged in a Beckman SW50 rotor at 50,000 rpm for
17 h at 4 °C. Fractions (~0.2 ml) were collected from the
bottoms of the tubes. Aliquots (20 µl) of odd-numbered fractions were
analyzed by SDS-PAGE. Polypeptides were visualized by staining with
Coomassie Blue dye. The identities of the polypeptides are denoted by
arrows on the left. C, ternary complex
formation. His-Pct1 (20 µg), Spt5(801-990) (40 µg), and Pce1 (10 µg) were incubated in various combinations with nickel-agarose beads.
The polypeptide compositions of the bead-bound fractions were analyzed
by SDS-PAGE (top panel; 50% of the bound fraction analyzed
in each lane). The identities of the polypeptides are denoted by
arrows on the right. Aliquots (1 µl) of the
imidazole eluates were assayed for guanylyltransferase activity in
reaction mixtures (20 µl) containing 50 mM Tris-HCl, pH
8.0, 5 mM MgCl2, 5 mM DTT, and 0.17 µM [ -32P]GTP. The mixtures were
incubated for 10 min at 37 °C, and the reactions were halted by
adding SDS to 1% final concentration. The samples were analyzed by
SDS-PAGE. The Pce1-32P[GMP] complex was visualized by
autoradiography of the gel.
|
|
Thus, recombinant Pce1 and Spt5(801-990) were produced in bacteria as
His6-Smt3 fusion proteins and purified from soluble bacterial extracts by nickel-agarose chromatography. The
His6-Smt3 domains were then removed by treatment of the
recombinant protein with purified His-tagged Ulp1, a Smt3-specific
protease that hydrolyzes the polypeptide chain at the junction between
His6-Smt3 and the fused downstream protein (25).
Re-chromatography of the digests on nickel-agarose resulted in
purification of the "tag-free" Pce1 and Spt5(801-990) proteins,
which were recovered in the flow-through and resolved from the
His6-Smt3 and His-Ulp1 proteins, which were retained on the
resin (data not shown). The native sizes of the purified proteins were
then investigated by sedimentation through glycerol gradients. Marker
proteins catalase (248 kDa), bovine serum albumin (66 kDa), and
cytochrome c (13 kDa) were included as internal standards.
After centrifugation, the polypeptide compositions of the odd-numbered
gradient fractions were analyzed by SDS-PAGE. The Spt5(801-990)
polypeptide (calculated size = 20 kDa) sedimented as a discrete
peak coincident with cytochrome c (Fig. 7A). We surmise that the native non-tagged Spt5(801-990) protein is a monomer.
(Note that the migration of the Spt5(801-990) polypeptide during
SDS-PAGE was aberrantly slow, perhaps because of the presence of
reiterated proline-containing motifs. Also, the Spt5(801-990) polypeptide migrated as a doublet composed of a predominant "fast" species and a minority "slow" species. Because Ulp1 processing of
the tagged recombinant His6-Smt3 fusion proteins is highly site-specific (25), we doubt that the doublet arises from heterogeneity at the N terminus of Spt5(801-990). We suspect that the doublet may
reflect conformational heterogeneity of the prolines.) The 47-kDa Pce1
protein sedimented as a discrete peak just slightly behind the bovine
serum albumin peak (Fig. 7B), consistent with a monomeric
structure, as suggested previously (26).
To measure ternary complex formation, His-Pct1 (a homodimer) was mixed
with Spt5(801-990) and adsorbed to nickel-agarose beads. After the
removal of unbound material, the beads were incubated with Pce1 and
then washed again to remove unbound protein. The material retained on
the beads was eluted under native conditions with 250 mM
imidazole. The polypeptide compositions of the eluates were analyzed by
SDS-PAGE; the eluate fractions were also assayed for
guanylyltransferase activity, evinced by the transfer of
[32P]GMP from [
-32P]GTP to the Pce1
polypeptide to form the covalent Pce1-GMP reaction intermediate (Fig.
7C). The salient findings were as follows: (i) neither
Spt5(801-990) nor Pce1 were bound to the beads in the absence of
His-Pct1; (ii) Spt5(801-990) bound to the beads in the presence of
His-Pct1; and (iii) Pce1 did not bind to the beads in the presence of
His-Pct1 unless Spt5(801-990) was also present
in the binding reaction mixture (Fig. 7C). Although the amount of Pce1 protein retained on the beads was much less than the
total amount of His-Pct1 present on the beads, it was in the same range
(based on staining) as the amount of Spt5(801-990), indicating that
the binding of the guanylyltransferase was limited principally by the
interaction of the monomeric Spt5 CTD with His-Pct1. We conclude that
binding of the capping enzymes to the Spt5 CTD is not mutually
exclusive but can occur simultaneously.
 |
DISCUSSION |
The present study contributes to an emerging picture of how
transcription elongation control is connected to cotranscriptional mRNA processing via physical interactions between Pol-II elongation factors and RNA modifying enzymes. We show that fission yeast RNA
triphosphatase and RNA guanylyltransferase interact independently with
the elongation factor Spt5. These findings provide a rationale for the
arrest and subsequent reactivation of Pol-II elongation at promoter
proximal sites.
Advantage accrues from a mechanism whereby the commitment of Pol-II to
processive elongation is contingent on prior acquisition of a cap. The
cap promotes downstream mRNA processing steps, especially the
splicing of the 5'-proximal intron (29, 30), and it protects mRNA
from exonucleolytic decay (31). If Pol-II commits prematurely to
traversing the entire transcription unit (covering megabase distances
in some metazoan genes) without the benefit of a cap, it runs the risk
of failing to excise the first intron in a timely fashion or perhaps at
all, a process that would yield a nonfunctional transcript. Accelerated
5'-3' decay of unguanylated nascent RNAs would also result in a futile
round of transcription.
Wasteful commitment of Pol-II is apparently avoided by the imposition
of an elongation checkpoint, whereby Spt5/Spt4 (DSIF) plus other
negative factors arrest the elongation complex shortly after promoter
clearance. This step is especially relevant to the control of HIV gene
expression, but recent studies highlight the general localization of
Spt5 on actively transcribed cellular genes (32, 33). They also suggest
a role for Spt5 in arresting Pol-II at promoter-proximal sites on
uninduced heat-shock genes (33). The importance of elongation arrest in
Spt5 action in vivo is underscored by the finding that a
missense mutation in zebrafish Spt5 that specifically prevents its
action as a negative elongation factor elicits a phenotype of aberrant
neuronal development (34). It is conceivable that the mutant animals
are defective in down-regulating elongation in certain Pol-II genes or
in developing neurons or that uncapped (and therefore nonfunctional)
transcripts are generated from certain Pol-II genes in the absence of
Spt5-induced elongation arrest.
Spt5 had not been studied previously in fission yeast. Here we
identified S. pombe Spt5 in a library screen for proteins
that bind to the fission yeast capping enzymes. We showed that Spt5 is
essential for viability of S. pombe, as it is in budding
yeast (35, 36), and that it interacts in vivo with the
previously uncharacterized S. pombe equivalent of Spt4.
Although our in vitro studies show that Spt4 is not required
for Spt5 binding to the capping enzymes, we suspect that Spt5 interacts
with the capping enzymes in vivo as part of an Spt5/Spt4
complex because the binding sites for Spt4 and the capping enzymes are
located on distinct functional domains of the 990-amino acid Spt5
polypeptide. We mapped the Spt4 binding site to the segment of Spt5
from amino acids 165-400. This region corresponds to the Spt4 binding
site in human Spt5 (16).
Wen and Shatkin (13) isolated hSpt5 in a two-hybrid screen using
mammalian capping enzyme as bait. Our findings suggest that the nexus
between capping enzymes and Spt5 is conserved across a wide
evolutionary landscape. Nonetheless, there are differences in how the
mammalian and fission yeast capping enzymes interact with Spt5. Wen and
Shatkin found that the C-terminal domain hSpt5(767-1087) was essential
for binding in the two-hybrid assay and that a second segment
hSpt5(111-197) near the amino end is also involved. Yet, in the
S. pombe system, only the Spt5 CTD is required for binding to the capping enzymes in the two-hybrid assay and in
vitro.
An alignment of the primary structure of the CTD of S. pombe
Spt5 to that of human Spt5 and the Spt5 orthologs of
Caenorhabditis elegans and D. rerio reveals
similarities as well as notable differences (Fig.
8). The fission yeast and metazoan Spt5
proteins contain a series of Thr-Pro and Ser-Pro dipeptides
(highlighted in shaded boxes in Fig. 8). The intervals
between the dipeptide repeats are different among metazoan species, and
they also differ from the regular nonamer spacing in S. pombe Spt5 (Fig. 8). The metazoan repeats do not adhere to the
S. pombe consensus sequence TPAWNSGSK (Fig. 8). In
particular, whereas the residue located two positions downstream of the
Thr-Pro dipeptide in S. pombe Spt5 is typically a tryptophan
(Fig. 4), it is never a tryptophan in the human, nematode, or zebrafish
proteins; instead, this position is usually occupied by tyrosine or
histidine (Fig. 8).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 8.
Comparison of the fission yeast and metazoan
Spt5 carboxyl repeat domains. The amino acid sequence of S. pombe Spt5 (Spo) from residues 799 to 990 is aligned to
the sequences of the Spt5 polypeptides of Homo sapiens
(Hsa), C. elegans (Cel), and D. rerio (Dre). Gaps in the alignment are indicated by
dashes (-). Positions of side chain identity/similarity in all four
Spt5 proteins are denoted by dots ( ). Series of conserved
(Thr/Ser)-Pro dipeptides are highlighted in shaded
boxes.
|
|
The regularity and specific amino acid composition of the S. pombe nonamer array may contribute to the avid binding of S. pombe Spt5 to the S. pombe capping enzymes. Indeed, we
detected no binding of the RNA triphosphatase domain of mammalian
capping enzyme to the S. pombe GST-Spt5(801-990) fusion
protein using conditions under which S. pombe Pct1 binds
Spt5 avidly.2 We detected
only trace binding of the guanylyltransferase domain of mammalian
capping enzyme to S. pombe GST-Spt5(801-990).2
Given that the individual triphosphatase and guanylyltransferase domains of mammalian capping enzyme bind in vitro to
mammalian Spt5 (13), our results suggest that the structural basis for the Spt5-capping enzyme interaction is distinct in fission yeast versus mammals.
hSpt5 up-regulates the guanylyltransferase activity of full-length
mammalian capping enzyme but not of the isolated C-terminal guanylyltransferase domain (13). The mammalian triphosphatase domain is
apparently required in cis for the stimulatory effect of
hSpt5 on the mammalian guanylyltransferase. We found that that S. pombe Spt5 had no effect on the guanylyltransferase activity of
Pce1, which is sensible in relation to mammalian results given that:
(i) Pce1 is a structural counterpart of the isolated mammalian guanylyltransferase domain and (ii) the S. pombe
triphosphatase Pct1 has no structural similarity whatsoever to the
mammalian triphosphatase domain (28, 37).
Although the Ser-Pro dipeptides within the heptad repeats of the Pol-II
CTD and the Thr-Pro dipeptides in the Spt5 CTD are both targeted for
phosphorylation by cyclin-dependent kinases, including
P-TEFb (21-23), there is a radical difference in the requirements for
phosphorylation in the interactions of the S. pombe capping
enzymes with the Pol-II CTD versus Spt5 CTD. Binding of Pct1
and Pce1 to Pol-II CTD requires serine phosphorylation and is optimal
when both Ser-2 and Ser-5 are phosphorylated (12). In contrast, Pct1
and Pce1 bind tightly to unmodified recombinant Spt5 CTD produced in
bacteria. Whether phosphorylation of Spt5 CTD modulates the affinity of
the capping enzymes for Spt5 remains to be determined.
Spt5 in the context of DSIF interacts with RNA polymerase and, together
with negative elongation factor, slows elongation. This provides a
kinetic window during which the capping enzymes can be recruited to the
elongation complex, via contacts with the Spt5 CTD and also with the
Pol-II CTD-PO4 that was formed by the TFIIH-associated
kinase during transcription initiation and promoter clearance. We posit
that cap formation occurs on the nascent chains within the arrested
Pol-II complexes. It remains to be discovered if and how the presence
of the capping enzymes in the elongation complex, or the presence of
cap on the nascent transcript, is implicated in the conversion of the
Spt5-arrested yeast transcription complex into a processive elongation
complex. By analogy with the mammalian system (20), the proper
positioning and/or activation of a P-TEFb-like factor might trigger its
phosphorylation of the Spt5 CTD as well as further phosphorylation of
the Pol-II CTD, thereby releasing the elongation complex from the
arrest. The P-TEFb equivalent has yet to be identified and
characterized in fission yeast.
 |
FOOTNOTES |
*
This work was supported by the National Institutes of Health
Grant GM52470.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. E-mail:
s-shuman@ ski.mskcc.org.
Published, JBC Papers in Press, March 13, 2002, DOI 10.1074/jbc.M200015200
2
Y. Pei and S. Shuman, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
Pol-II, polymerase
II;
CTD, C-terminal domain;
HIV, human immunodeficiency virus;
DSIF, DRB sensitivity-inducing factor;
DRB, 5,6-dichloro-1-D-ribofuranosylbenzimidazole;
P-TEFb, positive transcription elongation factor b;
AD, activation domain;
BD, binding domain;
Ni-NTA, nickel-nitrilotriacetic acid;
GST, glutathione
S-transferase;
DTT, dithiothreitol;
NELF-, negative
elongation factor.
 |
REFERENCES |
| 1.
|
Shuman, S.
(2000)
Prog. Nucleic Acid Res. Mol. Biol.
66,
1-40
|
| 2.
|
McCracken, S.,
Fong, N.,
Rosonina, E.,
Yankulov, K.,
Brothers, G.,
Siderovski, D.,
Hessel, A.,
Foster, S.,
Shuman, S.,
and Bentley, D. L.
(1997)
Genes Dev.
11,
3306-3318[Abstract/Free Full Text]
|
| 3.
|
Cho, E.,
Takagi, T.,
Moore, C. R.,
and Buratowski, S.
(1997)
Genes Dev.
11,
3319-3326[Abstract/Free Full Text]
|
| 4.
|
Yue, Z.,
Maldonado, E.,
Pillutla, R.,
Cho, H.,
Reinberg, D.,
and Shatkin, A. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12898-12903[Abstract/Free Full Text]
|
| 5.
|
Ho, C. K.,
Sriskanda, V.,
McCracken, S.,
Bentley, D.,
Schwer, B.,
and Shuman, S.
(1998)
J. Biol. Chem.
273,
9577-9585[Abstract/Free Full Text]
|
| 6.
|
Schroeder, S.,
Schwer, B.,
Shuman, S.,
and Bentley, D.
(2000)
Genes Dev.
14,
2435-2440[Abstract/Free Full Text]
|
| 7.
|
Cho, E.,
Rodriguez, C. R.,
Takagi, T.,
and Buratowski, S.
(1998)
Genes Dev.
12,
3482-3487[Abstract/Free Full Text]
|
| 8.
|
Lehman, K.,
Schwer, B., Ho, C. K.,
Rouzankina, I.,
and Shuman, S.
(1999)
J. Biol. Chem.
274,
22668-22678[Abstract/Free Full Text]
|
| 9.
|
Ho, C. K.,
Schwer, B.,
and Shuman, S.
(1998)
Mol. Cell. Biol.
18,
5189-5198[Abstract/Free Full Text]
|
| 10.
|
Ho, C. K.,
Lehman, K.,
and Shuman, S.
(1999)
Nucleic Acids Res.
27,
4671-4678[Abstract/Free Full Text]
|
| 11.
|
Ho, C. K.,
and Shuman, S.
(1999)
Molecular Cell
3,
405-411[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Pei, Y.,
Hausmann, S., Ho, C. K.,
Schwer, B.,
and Shuman, S.
(2001)
J. Biol. Chem.
276,
28075-28082[Abstract/Free Full Text]
|
| 13.
|
Wen, Y.,
and Shatkin, A. J.
(1999)
Genes Dev.
13,
1774-1779[Abstract/Free Full Text]
|
| 14.
|
Chiu, Y. L.,
Coronel, E., Ho, C. K.,
Shuman, S.,
and Rana, T. M.
(2001)
J. Biol. Chem.
276,
12959-12966[Abstract/Free Full Text]
|
| 15.
|
Wada, T.,
Takagi, T.,
Yamaguchi, Y.,
Ferdous, A.,
Imai, T.,
Hirose, S.,
Sugimoto, S.,
Yano, K.,
Hartzog, G. A.,
Winston, F.,
Buratowski, S.,
and Handa, H.
(1998)
Genes Dev.
12,
343-356[Abstract/Free Full Text]
|
| 16.
|
Yamaguchi, Y.,
Wada, T.,
Watanabe, D.,
Takagi, T.,
Hasegawa, J.,
and Handa, H.
(1999)
J. Biol. Chem.
274,
8085-8092[Abstract/Free Full Text]
|
| 17.
|
Yamaguchi, Y.,
Takagi, T.,
Wada, T.,
Yano, K.,
Furuya, A.,
Sugimoto, S.,
Hasegawa, J.,
and Handa, H.
(1999)
Cell
97,
41-51[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Renner, D. B.,
Yamaguchi, Y.,
Wada, T.,
Handa, H.,
and Price, D. H.
(2001)
J. Biol. Chem.
276,
42601-42609[Abstract/Free Full Text]
|
| 19.
|
Wada, T.,
Takagi, T.,
Yamaguchi, Y.,
Watanabe, D.,
and Handa, H.
(1998)
EMBO J.
17,
7395-7403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Price, D. H.
(2000)
Mol. Cell. Biol.
20,
2629-2634[Free Full Text]
|
| 21.
|
Ivanov, D.,
Kwak, Y. T.,
Guo, J.,
and Gaynor, R. B.
(2000)
Mol. Cell. Biol.
20,
2970-2983[Abstract/Free Full Text]
|
| 22.
|
Ping, Y.,
and Rana, T. M.
(2001)
J. Biol. Chem.
276,
12951-12958[Abstract/Free Full Text]
|
| 23.
|
Kim, J. B.,
and Sharp, P. A.
(2001)
J. Biol. Chem.
276,
12317-12323[Abstract/Free Full Text]
|
| 24.
|
Pei, Y.,
Schwer, B.,
Hausmann, S.,
and Shuman, S.
(2001)
Nucleic Acids Res.
29,
387-396[Abstract/Free Full Text]
|
| 25.
|
Mossessova, E.,
and Lima, C. D.
(2000)
Mol. Cell
5,
865-876[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Shuman, S.,
Liu, Y.,
and Schwer, B.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12046-12050[Abstract/Free Full Text]
|
| 27.
|
Håkansson, K.,
Doherty, A. J.,
Shuman, S.,
and Wigley, D. B.
(1997)
Cell
89,
545-553[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Lima, C. D.,
Wang, L. K.,
and Shuman, S.
(1999)
Cell
99,
533-543[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Ohno, M.,
Sakamoto, H.,
and Shimura, Y.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
5187-5191[Abstract/Free Full Text]
|
| 30.
|
Inoue, K.,
Ohno, M.,
Sakamoto, H.,
and Shimura, Y.
(1989)
Genes Dev.
3,
1472-1479[Abstract/Free Full Text]
|
| 31.
|
Schwer, B.,
Mao, X.,
and Shuman, S.
(1998)
Nucleic Acids Res.
26,
2050-2057[Abstract/Free Full Text]
|
| 32.
|
Kaplan, C. D.,
Morris, J. R., Wu, C.,
and Winston, F.
(2000)
Genes Dev.
14,
2623-2634[Abstract/Free Full Text]
|
| 33.
|
Andrulis, E. D.,
Guzman, E.,
Döring, P.,
Werner, J.,
and Lis, J. T.
(2000)
Genes Dev.
14,
2635-2649[Abstract/Free Full Text]
|
| 34.
|
Guo, S.,
Tamaguchi, Y.,
Schilbach, S.,
Wada, T.,
Lee, J.,
Goddard, A.,
French, D.,
Handa, H.,
and Rosenthal, A.
(2000)
Nature
408,
366-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Swanson, M. S.,
Malone, E. A.,
and Winston, F.
(1991)
Mol. Cell. Biol.
11,
3009-3019[Abstract/Free Full Text]
|
| 36.
|
Hartzog, G. A.,
Wada, T.,
Handa, H.,
and Winston, F.
(1998)
Genes Dev.
12,
257-269
|
| 37.
|
Changela, A., Ho, C. K.,
Martins, A.,
Shuman, S.,
and Mondragon, A.
(2001)
EMBO J.
20,
2575-2586[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Kaneko, C. Chu, A. J. Shatkin, and J. L. Manley
Human capping enzyme promotes formation of transcriptional R loops in vitro
PNAS,
November 6, 2007;
104(45):
17620 - 17625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Amir-Zilberstein, E. Ainbinder, L. Toube, Y. Yamaguchi, H. Handa, and R. Dikstein
Differential Regulation of NF-{kappa}B by Elongation Factors Is Determined by Core Promoter Type
Mol. Cell. Biol.,
July 15, 2007;
27(14):
5246 - 5259.
[Abstract]
[Full Text]
[PDF]
|
 |
|